Clementia

25 articles about Clementia

• 

  Montreal-based Biotech Snags $50M to Build Team of "Drug Hunters"

  2/8/2022

  The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.

• Ipsen Completes Acquisition of Clementia Pharmaceuticals

  4/18/2019

  Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients

• Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders

  3/7/2019

  Clementia Pharmaceuticals Inc. is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of Ipsen S.A. is proposing to acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share.

• Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

  2/25/2019

  Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020

• 

  Ipsen Strikes Deal to Acquire Clementia for $1.31 Billion, Sends Stocks Soaring

  2/25/2019

  This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.

• Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy VolunteersData from Study Expected in Q1 2019

  10/2/2018

  Clementia Pharmaceuticals Inc. today announced the initiation of a Phase 1 clinical trial evaluating an eye drop formulation of palovarotene in healthy volunteers.

• Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors

  1/31/2018

  Mr. Legault is an accomplished leader in the biopharmaceutical industry with a proven track record.

• Clementia Initiates Pivotal Phase III MOVE Trial for Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva

  12/12/2017

  Palovarotene, Clementia’s lead product candidate, is a retinoic acid receptor gamma agonist being investigated as a treatment for patients with ultra-rare and debilitating bone diseases.

• Clementia Announces Date of Corporate Update Conference Call

  12/5/2017

  Management will host a conference call and webcast at 8:30 a.m. ET on Tuesday, Dec. 12, 2017.

• Clementia Reports Third Quarter 2017 Financial Results and Business Highlights

  11/13/2017

  As of September 30, 2017, Clementia had cash and investments of $152.2 million, which includes the $128.2 million raised in Clementia’s IPO completed in August.

• Clementia Announces Closing Of Over-Allotment Option In Its Initial Public Offering

  8/21/2017

• Clementia to Launch IPO, Despite So-So Phase II Trials and Investor Skepticism

  8/1/2017

• Clementia Release: Phase II Part A Open Label Extension Trial Of Palovarotene For Treatment Of Patients With Fibrodysplasia Ossificans Progressiva Continues Positive Trends

  3/28/2017

• Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

  10/14/2016

• Clementia Release: Positive Effects Of Palovarotene On Spontaneous Heterotopic Ossification, Mobility, And Skeletal Growth In Mouse Models Of FOP Reported In Journal Of Bone And Mineral Research

  4/14/2016

• Clementia Announces Last Patient Enrolled In Phase 2 Trial Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva

  2/29/2016

• Clementia Expands Ongoing Phase 2 Study To Include Children With Fibrodysplasia Ossificans Progressiva (FOP)

  8/25/2015

• Clementia Rakes in $60M for Pipeline Development

  6/23/2015

• Clementia Advances Natural History Study Of Patients With Fibrodysplasia Ossificans Progressiva

  5/28/2015